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ABSTRACT
Purpose: Fibroblast growth factor receptor 3 (FGFR3)
mutations were reported recently at a high frequency in
low-grade urothelial cell carcinoma (UCC). We investigated
the feasibility of combining microsatellite analysis (MA) and
the FGFR3 status for the detection of UCC in voided urine.
Experimental Design: In a prospective setting, 59 UCC
tissues and matched urine samples were obtained, and sub-
jected to MA (23 markers) and FGFR3 mutation analysis
(exons 7, 10, and 15). In each case, a clinical record with tumor
and urine features was provided. Fifteen patients with a neg-
ative cystoscopy during follow-up served as controls.
Results: A mutation in the FGFR3 gene was found in 26
(44%) UCCs of which 22 concerned solitary pTaG1/2 le-
sions. These mutations were absent in the 15 G3 tumors. For
the 6 cases with leukocyturia, 46 microsatellite alterations
were found in the tumor. Only 1 of these was also detected
in the urine. This was 125 of 357 for the 53 cases without
leukocyte contamination. The sensitivity of MA on voided
urine was lower for FGFR3-positive UCC (15 of 21; 71%) as
compared with FGFR3 wild-type UCC (29 of 32; 91%). By
including the FGFR3 mutation, the sensitivity of molecular
cytology increased to 89% and was superior to the sensitiv-
ity of morphological cytology (25%) for every clinical sub-
division. The specificity was 14 of 15 (93%) for the two
(molecular and morphological) cytological approaches.
Conclusions: Molecular urine cytology by MA and
FGFR3 mutation analysis enables a highly sensitive and
specific detection of UCC. The similarity of molecular pro-
files in tumor and urine corroborate their clonal relation.
INTRODUCTION
UCC3 of the bladder is the fifth most common nonskin
malignancy in the Western world with54,300 new cases in the
United States per year (1). In most patients, UCC is superficial
at first presentation. After TUR, these patients require repeated
long-term surveillance, because up to 75% experiences one or
more recurrences, and 15–25% will progress to invasive UCC
(2–4). Cystoscopy currently remains standard practice for pri-
mary diagnosis and follow-up of UCC, but it is an uncomfort-
able, invasive, and expensive procedure. Although urinary cy-
tology is the most widely used method for noninvasive
detection, its application is limited by poor sensitivity, espe-
cially for low-grade UCC (5, 6). To enhance sensitivity, a wide
variety of biological markers has been developed, of which the
bladder tumor antigen and nuclear matrix protein 22 assays have
been extensively studied. However, current data on these uri-
nary tests do not justify their clinical integration (6, 7).
Microsatellites are tandem iterations of polymorphic di-,
tri-, or tetranucleotide repeats that are found frequently through-
out the genome. Microsatellite markers are altered in many
cancers reflected by LOH and MSI. In UCC, the chromosomal
arms 4p, 8p, 9p, 9q, 11p, and 17p often display LOH (8). In
contrast with other LOHs, loss of chromosome 9 is considered
an early event in bladder tumorigenesis, as it can be detected in
the majority of UCCs regardless of the histopathology (8–12).
In addition, it has become clear that the number of altered
microsatellite markers per UCC increases with parameters of
unfavorable clinical outcome (8, 9, 13).
Mao et al. (14, 15) and Steiner et al. (16) showed previously
the feasibility of MA for noninvasive detection of bladder cancer in
urine (14–16). Subsequently, several independent groups have
confirmed the superior sensitivity of MA (75–96%) compared with
morphological cytology (13–50%; Refs. 15–21). However, low-
grade and low-stage tumors are still sometimes missed by MA,
Received 5/8/02; revised 8/14/02; accepted 8/20/02.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
1 Supported by the University Hospital Rotterdam as part of a top-down
revolving fund project (FED 0930) and by grants from the Maurits and
Anna de Kock foundation, the Comite´ de Paris Ligue Nationale Contre
le Cancer (UMR 144, laboratoire associe´), the Centre National de la
Recherche Scientifique, and the Institut Curie.
2 To whom requests for reprints should be addressed, at Department of
Pathology, Josephine Nefkens Institute, Erasmus University, P.O. Box
1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-104087929; Fax:
31-104089487; E-mail: zwarthoff@path.fgg.eur.nl.
3 The abbreviations used are: UCC, urothelial cell carcinoma; TUR,
trans-urethral resection; LOH, loss of heterozygosity; MSI, micro-
satellite instability; MA, microsatellite analysis; FGFR, fibroblast
growth factor receptor; TNM, Tumor-Node-Metastasis; SSCP, single-
strand conformation polymorphism; AI, allelic-imbalance; CI, confi-
dence interval.
257Vol. 9, 257–263, January 2003 Clinical Cancer Research
especially if these tumors concern recurrent pTaG1 lesions, as these
are usually smaller than primary cancers (16, 20).
Activating FGFR3 gene mutations, responsible for several
inherited skeletal disorders, have been detected recently in blad-
der cancer (22–25). Surprisingly, somatic FGFR3 mutations in
UCC are related to favorable disease with 84% of pTaG1 tumors
having a mutation as compared with only 7% of pT2G3
tumors (25). Therefore, the detection of these mutations in urine
may provide an additional mode of noninvasive UCC detection
for “favorable” UCC. To our knowledge, no report exists on the
feasibility of FGFR3 mutation detection in urine.
In the present prospective study, we explored the possibil-
ity to improve the molecular cytology diagnosis of UCC by
addition of FGFR3 mutation analysis to MA of urine. We also
investigated the molecular profiles found in the tumor and the
corresponding urine. In addition, we compared our molecular
findings with multiple clinical variables.
PATIENTS AND METHODS
Patients. In a series of 51 patients who underwent sur-
gery at the University Hospital Rotterdam in 1998–2000, 59
UCCs were removed in a prospective setting. Voided urine
samples were obtained 1 day before surgery on admittance to
the clinic. The UCCs were graded according to the WHO
classification for urothelial neoplasms and staged according to
the TNM classification guidelines (26, 27). In case of multi-
focality, the papillary lesion with the highest grade/stage was
taken. The largest tumor was taken if grade/stage were the same
for multiple UCCs. Four patients had one recurrent UCC and 2
patients 2 recurrent UCCs. This population consisted of 41
males and 10 females with a mean age of 64.9 years (range,
35–89) at study entrance. TUR was performed in 54, cystec-
tomy in 4, and nephro-ureterectomy in 1 case(s), respectively. In
addition, 15 consecutive control patients with a negative cysto-
scopical examination who were in follow-up after superficial
UCC of different grades and who had a clean urinary sediment
at sample collection were included. This control population
consisted of 12 males and 3 females with a mean age of 65.1
years (range, 30–77) at cystoscopy. The patients signed written
informed consent before study inclusion. The medical ethical
committee of the Erasmus University and the University Hos-
pital Rotterdam approved the study (MEC 168.922/1998/55).
For morphological cytology, cells were stained by the standard
Pap staining procedure. The final diagnosis from the cytopa-
thology department of our hospital was used. These results were
obtained on a routine basis.
Sample Collection and DNA Extraction. Freshly
voided urine samples (25–100 ml) and venous blood (7 ml), as
a source of reference (germ-line) DNA, were collected from
each patient and stored at 4°C. Within 6 h after voiding, the
urine samples were divided and processed additionally for mor-
phological and molecular (MA and FGFR3 status) cytology. For
the molecular cytology, the urine and blood samples were han-
dled to obtain DNA as described before (20). Standard H&E
slides were made of the 59 paraffin-embedded tissue samples
for the microdissection procedure. The UCC tissue was manu-
ally dissected under a microscope avoiding contamination of the
DNA sample with regions of normal mucosa, leukocytes, or
stroma. The samples used for the molecular analyses contained
a minimum of 80% UCC cells, as assessed by histological
examination. This DNA was extracted using DNeasy Tissue kit
(Qiagen GmbH, Hilden, Germany). All of the DNA samples
were coded and stored at 30°C until use.
FGFR3 Mutation Analysis. FGFR3 mutation analysis
of the various DNA samples was performed in two institutes
(Josephine Nefkens Inst., Rotterdam and Inst. Curie, Paris,
France) by PCR-SSCP analysis as described (24, 25). In brief,
three regions encompassing activating FGFR3 mutations found
previously in severe skeletal dysplasia and UCC were amplified.
The primer sequences were as reported (24). The 32P-labeled
PCR products were separated on 6% polyacrylamide gels in
0.2 (exon 7) or 1 SSCP buffer (exons 10 and 15; 10 SSCP
buffer  0.5 M Tris-borate and 1 mM EDTA). The PCR-SSCP
procedure was checked by including the appropriate positive
DNA controls and H2O as a negative control. Samples with an
aberrant band at SSCP were sequenced with T7 Sequenase v2.0
(Amersham Life Science, Inc., Cleveland, OH) to check the
identity of the mutations. These analyses were carried out in a
blinded fashion, without knowledge of the clinical status.
MA. In a previous study, we selected 19 microsatellite
markers (ACTBP2, FGA, D16S476, D18S51, D4S243, D9S162,
D9S242, D9S252, D11S488, D9S171, D16S310, THO, D9S752,
D17S695, LPL, D9S144, D20S454, D17S786, and D17S960) by
their performance on control DNA, informativity, and frequency of
LOH in bladder cancer (20). These 19 markers are located on 12
chromosomal arms. In addition to these 19, we selected 4 micro-
satellite markers located within the FGFR3 gene (4p16.3) for this
study. The sequences of these 4 new primer pairs were as follows:
D4S412, F  5-ACTACCGCCAGGCACT and r  5-CTAA-
GATATGAAAACCTAAGGA; D4S1614, F  5-CAAATG-
CATCATGGCACATCT and r  5-ACCATGAGCATATTTC-
CATTTC; D4S3034, F  5-CTGCCAATAAACTGGGT and
r  5-TTGCTCACCAAAGAGGTT; and D4S3038, F  5-CT-
ATAGGGGGGTGAAGCAACAG and r  5-TGAGAGAAT-
ATGGCTATGTGGG. The annealing temperature for these 4
additional markers was 60°C. The PCR was performed as indicated
by the manufacturer of Taq-polymerase (Promega, Madison, WI).
ThePCRproductswereseparatedondenaturing6%polyacrylamide-
urea gels. We performed a quantitative analysis to determine the AI
ratio between blood:tumor and blood:urine DNA using the Phos-
phorImager system and the ImageQuant software (Molecular Dy-
namics Inc., Sunnyvale, CA). LOH was scored in informative cases
if a reduction of 30% in the AI ratio of the signals from tumor or
urine alleles was calculated in comparison with the corresponding
reference (blood) alleles. MSI was scored if a deletion or expansion
of a repeat unit was found as a new band on the gel. Every
microsatellite alteration (LOH and/or MSI) was confirmed by a
second PCR. The AI ratio closest to 1.0 was entered into the
database. The microsatellite analyses were performed in the Jose-
phine Nefkens Institute, Rotterdam. These analyses were also done
in a blinded fashion, without knowledge of the clinical status.
Statistical Analysis. The statistical package for social sci-
ences 9.0 (SPSS Inc., Chicago, IL) computer software was used for
data documentation and analysis. The 2 test and ANOVA (for
comparison of means) were used to analyze the possible correla-
tions between clinical variables, FGFR3 status, and microsatellite
alterations. A proportional correction for the number of noninfor-
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mative (homozygote) cases at MA was performed when we com-
pared the mean number of microsatellite alterations for distinct
variables. Statistical significance was assumed if P  0.05.
RESULTS
We have tested 59 UCC tissue samples, and the matched
urine DNA with MA and FGFR3 mutation screening. In addi-
tion, 15 control patients were included to determine the speci-
ficity of the molecular UCC diagnosis in urine.
FGFR3 Status and Microsatellite Alterations in Tumor.
In the 59 UCCs analyzed, we found 26 (44%) mutations in the
FGFR3 gene. The mutations resulted in the amino acid changes
R248C (n  2), S249C (n  22), and G372C (n  2). No
activating mutations were found in the 51 DNA samples from
venous blood indicating the somatic nature of FGFR3 mutations
in UCC. In the 8 recurrent UCCs, the same mutations (S249C,
three times) were detected as in the first tumor. Five recurrent
cases had no mutation, which was in line with the FGFR3 status
of their previous tumor(s). Most (85%) mutations were identi-
fied in solitary pTaG1/2 UCC, whereas in none of 15 grade 3
UCCs were these mutations found (Table 1). There was no
correlation between the FGFR3 mutation and tumor size or
primary/recurrent UCC (Table 1). MA of the 59 tumors revealed
MSI for 7 markers and LOH for 396. Only 2 tumors had no
alteration in any of the 23 microsatellite markers confirming that
LOH is very frequent in UCC. There was no relation between
LOH at a specific chromosomal arm and primary/recurrent
UCC, tumor size, or multifocality (data not shown). Yet, the
microsatellite alterations on the chromosomal arms 4p, 11q,
17p, and 20q were related to higher-stage UCC; Ps (2): 0.035,
0.035, 0.001, and 0.016, respectively, and the alterations on
the chromosomal arms 4q and 17p were related to higher-grade
UCC; Ps (2): 0.049 and 0.001, respectively. Twenty-eight
UCCs had microsatellite alterations at 17p (14 of 15 tumors
staged pT1; 11 of 28 G2 and 14 of 15 G3 UCCs). In addition,
MA revealed significant relations between the mean number of
altered markers, and tumor stage (P  0.002) and grade (P 
0.001; Table 1). Conversely, the mean number of altered mark-
ers was significantly lower in FGFR3 mutant tumors as in-
dicated by Fig. 1 (P  0.006). Taken together, the above-
presented data provide strong evidence for the association of the
FGFR3 mutation with a more favorable kind of UCC.
FGFR3 Mutation and LOH at 4p16.3. We also ana-
lyzed the possible relationship between LOH in the FGFR3
gene (chromosomal location: 4p16.3) and a mutation of FGFR3.
Fig. 1 Correlation FGFR3 mutation and number of altered microsat-
ellite markers in UCC. The figure shows the mean number of micro-
satellite alterations for the 33 tumors without FGFR3 mutation, i.e., 8.1
alterations/tumor (95% CI, 6.6–9.6), and for the 26 tumors with a
mutation in the FGFR3 gene, i.e., 5.2 alterations/tumor (95% CI, 4.0–
6.4); bars, CI for mean.
Table 1 Correlation of clinical tumor characteristics with molecular findings in tumor tissue
FGFR3 status Microsatellite analysis
No
mutation Mutation P (2)
Mean number of altered markers
(95% CI for mean)
P
(ANOVA)
UCC
Primary 14 12 0.775 7.5 (5.9–9.0) 0.293
Recurrent 19 14 6.3 (4.8–7.8)
Tumor size
0.5 cm 11 7 0.781 7.1 (5.3–8.9) 0.253
0.5–2.0 cm 10 10 5.7 (3.4–7.9)
	2.0 cm 12 9 7.7 (6.1–9.3)
Number of tumors
Solitary 16 22 0.004 6.6 (5.4–7.9) 0.664
Multiple 17 4 7.1 (5.1–9.1)
Tumor stage
pTa 18 26 0.001 5.9 (4.8–7.0) 0.002
pT1a 15 0 9.6 (7.2–12.0)
Tumor grade
G1 8 13 0.001 4.3 (3.0–5.6) 0.001
G2 10 13 7.9 (6.0–9.7)
G3 15 0 8.8 (6.8–10.8)
Total 33 26 6.8 (5.8–7.9)
a pT1 in 3, pT2 in 8, pT3 in 2, and pT4 in 1 case(s).
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Fifteen (25%) of the 59 analyzed UCCs had LOH at 4p16.3.
Only 7 of these 15 also displayed a mutation in the FGFR3 gene.
As a consequence, 19 of 26 patients with a mutation had no
LOH at 4p16.3. Moreover, in contrast with the FGFR3 muta-
tion, we found no association between a clinical variable, i.e.,
primary/recurrent UCC, multifocality, size, stage, or grade, and
LOH at 4p16.3. These data suggest that the occurrence of LOH
at 4p16.3 and the FGFR3 mutation are separate events in UCC
tumorigenesis as reported recently by Sibley et al. (23).
Molecular and Morphological Cytology. Several rep-
resentative examples of the molecular analyses on tumor and
urine DNA, and the corresponding clinical records are given in
Fig. 2. We investigated whether the presence of leukocytes had
an impact on the outcome of our urine analyses. In 6 of the 59
urine samples, 	50 leukocytes per microscopic view (magnifi-
cation 400) were found (example Fig. 2D). Both molecular
(MA and FGFR3 status) and morphological cytology detected
only 1 of these 6 cases. Therefore, we excluded these 6 cases.
For the remaining 53 urine samples, the sensitivity of MA, the
FGFR3 mutation, and morphological cytology were 44 of 53
(83%), 11 of 53 (21%), and 13 of 51 (25%), respectively. In this
group of 53 UCCs, 21 tumors were found to have a FGFR3
mutation. Eleven of these displayed the same mutation in the
urine, whereas the 32 FGFR3 wild-type tumors displayed no
mutations in the urine. Because the sensitivity of MA was lower
for UCCs with FGFR3 mutation (15 of 21; 71%) compared with
FGFR3 wild-type UCC (29 of 32; 91%), we explored the
possibility to combine MA and FGFR3 mutation screening to
enhance the sensitivity. Indeed, we detected 3 more UCCs by
including the FGFR3 status to the MA of urine. Consequently,
the molecular detection of FGFR3-positive UCC increased from
15 of 21 to 18 of 21, and the overall sensitivity of molecular
cytology increased to 47 of 53 (89%). The combination of
molecular cytology and morphological cytology did not addi-
tionally enhance the sensitivity or decrease the specificity (data
not shown). Table 2 shows the performance of molecular and
Fig. 2 Representative examples (A–F) of the molecular analyses on tumor and urine DNA, and the corresponding clinical records. Per case, the
FGFR3 mutations and the altered markers at MA are shown. In addition, at the bottom of each case, a clinical record is given. For the FGFR3 status,
a mutation is indicated by a box that contains the amino acid change caused by the mutation and the affected codon. Wild type (wt) indicates the
absence of a mutation in the investigated exons 7, 10, and 15 of the FGFR3 gene. For the MA, the altered markers in tumor and/or urine are presented.
Loss of the upper allele, loss of the lower allele, and MSI are indicated as shown at the bottom of the figure. No LOH (AI ratio 0.70) or MSI is
indicated by a white box. Noninformative markers are not shown. In the clinical record, information on the tumor, i.e., primary or recurrent lesion,
size, multifocality, pathological stage and grade, and localization, as well as information on the urine, i.e., morphological cytology diagnosis and
number of leukocytes per microscopic view in the urinary sediment, are given. A shows a FGFR3-positive tumor of the right upper urinary tract
(ureter) that is detected in the corresponding urine by FGFR3 mutation analysis and MA. B, a pTaG1 lesion, is not detected by MA but is detected
by the FGFR3 mutation analysis of the urine. In C, a LOH for the marker ACTBP2 was observed in the urine, which was not observed in the tumor.
D shows the MA of a bladder-tumor patient with leukocyturia. Next to multiple losses, example E shows MSI of tumor and urine for the marker
D11S488. F is the opposite of B. It shows a pTaG1 lesion that is detected by MA but not by FGFR3 mutation analysis of urine.
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morphological cytology for the different clinical and molecular
variables of the tumors. The superior sensitivity of the molecular
detection compared with the morphological approach is evident
for all of the clinical and molecular variables. Furthermore,
we determined the specificity of molecular and morphological
cytology on the urine samples of 15 patients who were in
follow-up after TUR of superficial UCC. These patients had a
negative cystoscopy and a clean (leukocytes: 0–10 per micro-
scopic view) sediment at time of urine collection. Fourteen of
these 15 had no microsatellite alterations, and FGFR3 mutations
and morphological cytology diagnosis was negative. Conse-
quently, the specificity of molecular and morphological cytol-
ogy was 93% (Table 2). In the 1 remaining patient, all three of
the urine analyses were positive. A tumor obtained from the
archive showed the same microsatellite alterations and the same
FGFR3 mutation as were found in the urine, suggesting that the
LOHs observed in the urine were caused by a recurrence that
preceded cystoscopical detection. In summary, the molecular
cytology by the MA and the FGFR3 mutation provided a highly
sensitive and specific mode of noninvasive UCC detection.
Comparison of Genetic Aberrations in Tumor and
Corresponding Urine. For the 53 patients without leukocy-
turia, we found 141 microsatellite alterations and 13 FGFR3 mu-
tations in the urine. In every case, at least one match between urine
and tumor was found with both molecular methods. The AI ratios
obtained at the MA for tumor and urine are plotted against each
other in Fig. 3. In case of LOH for tumor and urine (n 125), the
same allele (upper or lower band on the gel) was always lost. In
addition, a LOH in urine, which was not observed in the analyzed
tumor, was only found in 16 of 914 (1.8%) of the informative cases
(Fig. 3). These data indicate that the urine contained the same
genetic aberrations as the analyzed tumor. We also observed that
the AI ratios in urine were generally higher (closer to 0.70) than the
AI ratios in tumor pointing to a so-called dilution effect caused by
the presence of normal and malignant cells in the urine. In this light,
it is not surprising that contamination of the urine by “normal”
leukocytes leads to a less-sensitive detection of UCC as reported in
the previous paragraph and in Table 3. In this table, we compared
the molecular findings in tumor and urine for the cases without and
with leukocyturia. Of the 357 microsatellite alterations in tumor,
125 (35%) were also found in the corresponding urine in case of no
leukocyturia. For patients with FGFR3 mutant tumors (33 of 100;
33%) and for patients with FGFR3 wild-type tumors (92 of 257;
36%) microsatellite alterations were also found in the correspond-
ing urine (P 0.20). Taking into account that UCCs characterized
by the presence of a FGFR3 mutation (see also Fig. 1) are associ-
ated with a lower number of microsatellite alterations, this provides
an additional explanation for the lower sensitivity of urinary MA in
case of “favorable” UCC. Furthermore, we investigated whether
the clinical variables had an influence on the detection of the same
alterations in the urine. If multifocality was present, significantly
more microsatellite (tumor) alterations were observed in urine. The
numbers were 62 of 132 (47%) in case of multiple tumors and
63 of 225 (28%) in case of a solitary lesion (P  0.001). In
contrast, no such differences were found for the other variables,
i.e., primary/recurrent UCC, size, stage, or grade.
In addition to the variables mentioned above, associated car-
cinoma in situ (present in 6 cases) was also considered. The stage
Fig. 3 Allelic (imbalance) ratios of tumor and urine for the 23 micro-
satellite markers. This scatterplot contains the microsatellite data of the
23 markers for the 53 UCC cases with no leukocyturia. In 305 cases, the
particular microsatellite marker was not informative (homozygote).
Thus, 914 informative cases remained. In 541 cases, no loss in tumor
and urine was observed. Sixteen cases showed an alteration (AI ratio
0.70) in urine, which was not found in the analyzed tumor. On the
other hand, 232 alterations were only detected in tumor. In 125 cases,
the tumor and the urine were found to contain LOH for the same allele.
For the samples below the dashed line (n 96), the AI ratio was higher,
i.e., closer to 0.70, in urine as compared with tumor.
Table 2 Molecular and morphological urine cytology for different
clinical and molecular tumor features
Molecular
cytologya
Morphological
cytologyb
UCC
Primary 22/23 (95) 8/21 (30)
Recurrent 25/30 (83) 5/30 (17)
Tumor size
0.5 cm 14/18 (78) 2/18 (11)
0.5–2.0 cm 14/16 (88) 3/16 (19)
	2.0 cm 19/19 (100) 8/17 (47)
Number of tumors
Solitary 30/34 (88) 4/32 (13)
Multiple 17/19 (89) 9/19 (47)
Tumor stage
pTa 34/39 (87) 7/38 (18)
pT1c 13/14 (93) 6/13 (46)
Tumor grade
G1 14/18 (78) 2/17 (12)
G2 20/21 (95) 4/21 (19)
G3 13/14 (93) 7/13 (54)
FGFR3 status (tumor)
Mutation 18/21 (86) 2/20 (10)
No mutation 29/32 (91) 11/31 (36)
Microsatellite analysis (tumor)
LOH/MSI 47/51 (92) 13/49 (27)
No LOH/MSI 0/2 (0) 0/2 (0)
Sensitivity total 47/53 (89) 13/51 (25)
Specificity total 14/15 (93) 14/15 (93)
a Combination of microsatellite analysis and FGFR3 mutation
detection in voided urine.
b In 2 cases, cytology diagnosis was not possible.
c See footnote Table 1.
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and grade of the papillary UCCs was as follows: pT1G2 in 1,
pT1G3 in 1, andpT2G3 in 4 case(s), respectively. None of these
tumors had a FGFR3 mutation, and no additional microsatellite
alterations or FGFR3 mutations in urine were seen for these cases.
DISCUSSION
Bladder cancer has a high incidence and requires continu-
ous clinical attention after initial treatment. The urine of these
patients may offer a convenient mode of noninvasive UCC
detection. However, morphological cytology and other urinary
tests approved by the FDA can only be used as adjuncts to
cystoscopy (5–7, 20). For this reason, research efforts for non-
invasive methods for detection and follow-up, which eventually
could reduce the number of bothersome cystoscopical examina-
tions, are still warranted.
The current study is to our knowledge the first to combine
FGFR3 mutation analysis and MA on matched tumor and
voided urine samples. We detected 26 FGFR3 mutations in 59
UCCs. These mutations were strongly associated with favorable
(solitary pTaG1/2) UCC. The association of the FGFR3 muta-
tion with a lower number of LOHs per tumor and the association
with solitary UCC additionally underlines the “favorable” na-
ture of tumors with a FGFR3 mutation found in two earlier
studies (24, 25). These two recent studies described the relation
of the FGFR3 mutation with low-stage and low-grade UCC, a
lower recurrence rate of superficial tumors in a series of 72
UCCs (24), and absence of FGFR3 mutations in 20 cases of
carcinoma in situ (the putative precursor of invasive UCC; Ref.
25). Moreover, only 4 of 28 UCCs with LOH on chromosome
17p simultaneously had a FGFR3 mutation in the present study.
As LOH at 17p (TP53 gene locus) is indicative for high-grade
and invasive UCC (Refs. 2, 9, 28; this study), this again pointed
to the favorable nature of UCC with the FGFR3 mutation.
The high incidence and the association of the FGFR3 muta-
tion with favorable UCC prompted us to explore its potential as a
molecular marker in urine. We chose to combine the FGFR3
mutation analysis to MA of urine because MA has proven to be a
very accurate molecular method for detection and follow-up of
UCC in the hands of several independent groups (14–21). Here we
reported the highest sensitivities for MA in large (100%), invasive
(93%), and poorly differentiated (93%) UCC. Similarly, Schneider
et al. (18), who evaluated MA in a large group of 183 patients, also
found the highest sensitivities in invasive (95%) and G3 (96%)
UCC. The sensitivities for the detection of G1 UCC by MA were
78% in the present study and 79% in the study by Schneider et al.
(18). Because we could enhance the sensitivity of molecular cytol-
ogy to 89% (47 of 53) by adding the FGFR3 mutation analysis,
without compromising the specificity (93%; 14 of 15), we advocate
the addition of the FGFR3 mutation analysis, particularly the exons
7 and 10, to MA of urine to optimize the molecular cytological
diagnosis for patients with low-grade UCC.
We compared the molecular profiles of our patients in UCC
tissue and the corresponding urine. Interestingly, additional alter-
ations in the urine, which were not observed in tumor tissue, were
only found in 16 of 914 (1.8%) cases for MA (23 markers) and 2
of 159 (1.3%) for FGFR3 mutation analyses (exons 7, 10, and 15).
These results show that tumor cells in the urine are clonally related
to the tumor(s) in the bladder. Earlier studies on smaller numbers of
UCCs and their corresponding urine samples also pointed to this
clonal relation (14–16). In addition, the data presented here show
that significantly more microsatellite alterations reappeared in the
urine if multifocality was present. Because we only analyzed 1
tumor in each case, this again provided an indication that multiple
tumors are clonally related. Our results are in line with other studies
that found clonal relations between multiple UCC (29, 30), upper
and lower tract UCC (10, 11), and metachronous UCC (31). In the
present study, 52% (11 of 21) of the FGFR3 mutations and 35%
(125 of 357) of the microsatellite alterations that were found in
tumor tissue were also present in the urine. Much higher percent-
ages (	80%) were reported in two studies using p53 mutations as
biomarkers (32, 33). This may indicate that tumor cells of UCC
with p53 mutations shed more easily than FGFR3 mutant tumor
cells. However, recently developed methods for the detection of
single nucleotide changes may additionally increase the sensitivity
for detection of FGFR3-positive UCC in urine (34).
In a previous study on MA for follow-up of superficial blad-
der cancer (20), we found that leukocyte abundance induced false-
negative results in MA. In this study, only 2% of the tumor-
associated microsatellite alterations were detected in urine if
leukocyturia was present. This was 35% for the patients with a
clean urinary sediment. Consequently, the contamination with
“normal” leukocyte DNA rendered the result unreliable. Surpris-
ingly, Christensen et al. (35) reported frequent (59%) MSI in urine
of patients with cystitis caused by benign prostatic hyperplasia. As
a possible explanation for their discrepant outcome, Christensen
et al. (35) pointed to the use of different (more prone to MSI)
microsatellites in their study. Nevertheless, leukocyte abundance
may be considered a drawback for the molecular cytology diagno-
sis in urine. Possibilities to circumvent this drawback were dis-
cussed before (20).
In conclusion, the clonal relation of UCC allows a detec-
tion of tumor activity in voided urine. We have shown that
molecular cytology by MA and FGFR3 gene analysis enables a
highly sensitive and equally specific detection of UCC com-
pared with morphological cytology. As molecular methods be-
come more available with the introduction of automated tech-
niques, our results and those of others strongly suggest that
PCR-based molecular cytology may be a useful tool to improve
the detection and monitoring of patients with UCC.
Table 3 Correlation of FGFR3 status and LOH between tumor and
urine, and the effect of leucocyte abundance
A. FGFR3 status
Mutation
(Tumor)
Same mutation (%)
(Urine) P (2)
Leuc. 50 (n  53) 21 11 (52%) P  0.033
Leuc. 50 (n  6) 5 0 (0%)
B. Microsatellite analysis
Microsatellite
alterations
(Tumor)
Same microsatellite
alteration (%)
(Urine)
P (2)
Leuc. 50 (n  53) 357 125 (35%) 0.001
Leuc. 50 (n  6) 46 1 (2%)
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